Body weight gain induced by atypical antipsychotics: an extension of the monocygotic twin and sib pair study

Gebhardt, Stefan; Theisen, Frank; Haberhausen, Michael; Heinzel‐Gutenbrunner, Monika; Wehmeier, Peter M.; Krieg, J.‐C.; Kühnau, Wolfgang; Schmidtke, Jörg; Remschmidt, Helmut; Hebebrand, Johannes

doi:10.1111/j.1365-2710.2009.01084.x

Cited by 86 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twin studies have led to suggestions of genetic variability in antipsychotic-induced weight gain (Gebhardt 2010). Genetic variations have been proposed for the HTR2C gene, which encodes for 5-HT 2C receptors.…”

Section: Antipsychoticinduced Weight Gainmentioning

confidence: 99%

Metabolic syndrome in psychiatry: advances in understanding and management

Ho¹,

Zhang²,

Mak³

et al. 2014

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryMetabolic syndrome comprises a number of cardiovascular risk factors that increase morbidity and mortality. The increase in incidence of the syndrome among psychiatric patients has been unanimously demonstrated in recent studies and it has become one of the greatest challenges in psychiatric practice. Besides the use of psychotropic drugs, factors such as genetic polymorphisms, inflammation, endocrinopathies and unhealthy lifestyle contribute to the association between metabolic syndrome and a number of psychiatric disorders. In this article, we review the current diagnostic criteria for metabolic syndrome and propose clinically useful guidelines for psychiatrists to identify and monitor patients who may have the syndrome. We also outline the relationship between metabolic syndrome and individual psychiatric disorders, and discuss advances in pharmacological treatment for the syndrome, such as metformin.LEARNING OBJECTIVES•Be familiar with the definition of metabolic syndrome and its parameters of measurement.•Appreciate how individual psychiatric disorders contribute to metabolic syndrome and vice versa.•Develop a framework for the prevention, screening and management of metabolic syndrome in psychiatric patients.

show abstract

Section: Antipsychoticinduced Weight Gainmentioning

confidence: 99%

Metabolic syndrome in psychiatry: advances in understanding and management

Ho¹,

Zhang²,

Mak³

et al. 2014

Adv. psychiatr. treat

View full text Add to dashboard Cite

show abstract

“…However, there are no reliable clinical predictors available in clinical practice. As results of twin studies indicate a genetic influence on AIWG, 11,12,121 numerous candidate studies have been performed during the past few years. Most consistent findings exist for an association between polymorphisms of the HTR2C gene and AIWG.…”

Section: Antipsychotic-induced Weight Gainmentioning

confidence: 99%

Pharmacogenetics of Antipsychotics

2014

View full text Add to dashboard Cite

Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment with APs and thus allowing for individualized treatment strategies. We highlight most important findings obtained through both candidate gene and genome-wide association studies, including pharmacokinetic and pharmacodynamic factors. Methods:We reviewed studies on pharmacogenetics of AP response and adverse effects published on PubMed until early 2012. Owing to the high number of published studies, we focused our review on findings that have been replicated in independent studies or are supported by meta-analyses.Results: Most robust findings were reported for associations between polymorphisms of the cytochrome P450 system, the dopamine and the serotonin transmitter systems, and dosage, treatment response, and adverse effects, such as AP-induced weight gain or tardive dyskinesia. These associations were either detected for specific medications or for classes of APs. Conclusion:First promising and robust results show that pharmacogenetics bear promise for a widespread use in future clinical practice. This will likely be achieved by developing algorithms that will include many genetic variants. However, further investigation is warranted to replicate and validate previous findings, as well as to identify new genetic variants involved in AP response and for replication of existing findings. W W W La pharmacogénétique des antipsychotiquesObjectif : Au cours des dernières décennies, des efforts croissants ont été déployés dans des études visant à percer l'influence des facteurs génétiques sur le dosage des antipsychotiques (AP), la réponse au traitement, et la survenue d'effets indésirables. Ces études voulaient améliorer les soins cliniques en prédisant le résultat du traitement par AP, et en donnant lieu ainsi à des stratégies de traitement individualisées. Nous présentons les résultats les plus importants obtenus par des études tant de gènes candidats que d'association pangénomique, notamment les facteurs pharmacocinétiques et pharmacodynamiques. Méthodes :Nous avons passé en revue les études sur la pharmacogénétique de la réponse aux AP et des effets indésirables publiées dans PubMed jusqu'au début de 2012. Vu le nombre élevé d'études publiées, notre revue a mis l'accent sur les résultats qui ont été reproduits dans des études indépendantes ou qui sont soutenus par des méta-analyses.

show abstract

“…The heritability (h 2 ) of AIWG is estimated to be 0.6-0.8 [16]. AIWG often coincides with the development of MetS, a complex phenotype characterized by central obesity, insulin resistance, hyperglycemia, dyslipidemia, and hypertension [8].…”

Section: Resultsmentioning

confidence: 99%

“…Evidence from twin studies implicates a significant genetic component underlying individual differences in susceptibility to AAEs [15,16]. Therefore, PGx has the potential to significantly improve the treatment of SCZ and other neuropsychiatric disorders.…”

Section: Introductionmentioning

confidence: 99%

Genetics of Common Antipsychotic-Induced Adverse Effects

MacNeil

Müller

2016

Complex Psychiatry

View full text Add to dashboard Cite

The effectiveness of antipsychotic drugs is limited due to accompanying adverse effects which can pose considerable health risks and lead to patient noncompliance. Pharmacogenetics (PGx) offers a means to identify genetic biomarkers that can predict individual susceptibility to antipsychotic-induced adverse effects (AAEs), thereby improving clinical outcomes. We reviewed the literature on the PGx of common AAEs from 2010 to 2015, placing emphasis on findings that have been independently replicated and which have additionally been listed to be of interest by PGx expert panels. Gene-drug associations meeting these criteria primarily pertain to metabolic dysregulation, extrapyramidal symptoms (EPS), and tardive dyskinesia (TD). Regarding metabolic dysregulation, results have reaffirmed HTR2C as a strong candidate with potential clinical utility, while MC4R and OGFR1 gene loci have emerged as new and promising biomarkers for the prediction of weight gain. As for EPS and TD, additional evidence has accumulated in support of an association with CYP2D6 metabolizer status. Furthermore, HSPG2 and DPP6 have been identified as candidate genes with the potential to predict differential susceptibility to TD. Overall, considerable progress has been made within the field of psychiatric PGx, with inroads toward the development of clinical tools that can mitigate AAEs. Going forward, studies placing a greater emphasis on multilocus effects will need to be conducted.

show abstract

Body weight gain induced by atypical antipsychotics: an extension of the monocygotic twin and sib pair study

Abstract: The results of the present and our previous report suggest a contribution of genetic factors in antipsychotic-induced weight gain of 60-80%.

Cited by 86 publications

References 24 publications

Metabolic syndrome in psychiatry: advances in understanding and management

Metabolic syndrome in psychiatry: advances in understanding and management

Pharmacogenetics of Antipsychotics

Genetics of Common Antipsychotic-Induced Adverse Effects

Contact Info

Product

Resources

About